Introduction
patients receiving maintenance haemodialysis (HD), the prevalence of CVD and cardiovascular (CV) mortality are far greater than in the general population [7] . However, traditional CV risk factors do not explain the increased risk and interventions such as lipid lowering with statin therapy have no benefit in this population [8, 9] , suggesting that the natural history and pathogenesis of CVD is different from the general population. In contrast, non-traditional, uraemia-related factors such as inflammation, low serum albumin levels, high serum phosphate, hyperparathyroidism (HPT) and vitamin D deficiency [10] [11] [12] [13] [14] [15] have been associated with CVD in patients on maintenance HD. However, most of these studies had significant limitations, such as small sample size or observational study design.
AURORA (a study to evaluate the use of rosuvastatin in subjects on regular haemodialysis: an assessment of survival and CV events) is the largest randomised controlled trial conducted in HD patients, with blinded, independent adjudication of endpoints, in which 2,776 HD patients were followed up for 4 years. Although the study failed to show any benefit of rosuvastatin therapy, it provides a unique resource in which to study the determinants of CVD in patients receiving HD. Thus, in the present report we have analysed the impact of traditional and non-traditional CV risk factors on CV outcomes in a large population of HD patients who participated in the AURORA study.
Materials and Methods

Design of the AURORA Study
The AURORA study design, main outcome findings, and baseline data have been described previously [8] . In short, AURORA recruited 2,776 HD patients (treated with HD for at least 3 months), aged 50-80 years, from 280 nephrology centres in 25 countries. Eligible patients were randomly assigned to receive either rosuvastatin 10 mg daily, or matching placebo. The mean length of follow-up was 3.2 years. Treatment with rosuvastatin was not associated with a reduction in the composite primary endpoint of major adverse cardiovascular events (MACE) [8] .
CV endpoints in AURORA included (i) time to MACE, which was a combined endpoint of non-fatal myocardial infarction and non-fatal stroke and of death from all CV causes. Again, death from all CV causes was defined as death from CHD (definite), CHD (suspected), other cardiac cause, other vascular cause, other CV cause, ischemic stroke, unclassified stroke and primary intracerebral haemorrhage, cerebellar haemorrhage or both.
Further CV endpoints in AURORA were (ii) time to atherosclerotic cardiac event (including definite or probable non-fatal myocardial infarction, and deaths due to CHD), and (iii) CV death (including death from all CV causes). All events were reviewed and adjudicated by an independent endpoint committee blinded to treatment allocation [8] . The study adhered to the International Conference on Harmonisation Guidelines for Good Clinical Practice and was conducted in accordance with the Declaration of Helsinki. All participants provided written informed consent, and the ethics committee at each participating centre approved the trial.
Risk Factor Analysis
All analyses were conducted using SAS statistics (SAS Institute, Cary, N.C., USA). The current risk factor analysis was conducted in both treatment arms combined, as there were no significant differences in CV events between the two treatment groups [8] . Potential risk factors included demographic characteristics (age, sex, body mass index (BMI), smoking, years on HD, Kt/V); co-morbid The body mass index (BMI) is the weight in kilograms divided by the square of the height in meters. Values are presented as mean ± SD or median (interquartile range), unless otherwise indicated. TC = Total cholesterol; HDL = high-density lipoprotein; LDL = low-density lipoprotein; ApoB/ApoA-1 = ratio of apolipoprotein B and apolipoprotein A-1; SBP = systolic blood pressure; DBP = diastolic blood pressure; PP = pulse pressure; Kt/V = dialyzer clearance of urea and dialysis time divided with volume of distribution of urea; CHD = coronary heart disease; CRP = C-reactive protein.
Schneider et al. 146 disease (diabetes mellitus, preexisting CHD); systolic (SBP) and diastolic (DBP) blood pressure, or pulse pressure (PP); information on use of concomitant medication (ACE inhibitors (ACEi), β-blocker, sevelamer); baseline routine laboratory assessments (haematocrit, haemoglobin, and serum calcium, phosphate, albumin, total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglyceride), and non-routinely used biomarkers (apolipoprotein-A1 (ApoA-1) and apolipoprotein-B (ApoB), oxidatively modified low-density cholesterol (OX-LDL), highly sensitive C-reactive protein (hsCRP)) ( table 1 ).
Determinants of CV endpoints were identified first by univariate Cox regression analysis, then hazard ratios (HR) with 95% confidence intervals and p values were generated for independent risk factors by using a stepwise Cox regression analysis. For parameters that were closely related (e.g. haemoglobin and haematocrit, PP and SBP or DBP, or ApoA-1 and HDL-C), single variables were inserted to identify the best fit in the multivariate analysis. Several potential risk factors were analysed for each outcome before model building. In the Cox multivariate model, the p value for inclusion and exclusion was set at 0.01.
Further, variable importance for MACE was calculated by using a random survival forest (RSF) model. RSF modelling reduces variance and bias by using all variables collected and assessing for non-linear effects and complex interactions.
Results
To identify CV risk factors in patients receiving maintenance HD, we analysed three major CV endpoints: MACE, atherosclerotic cardiac events and CV death ( tables 2-4 ).
Time to Major CV Event
In AURORA, the primary endpoint of MACE was recorded in 804 patients (18.7 events per 100 patient-years). The major univariate risk factors for this endpoint were age (HR 1.04), phosphate (HR 1.30), albumin (HR 0.92), 
Discussion
In patients receiving maintenance HD, two large-scale prospective trials, AURORA and 4D, have shown no benefit from statin treatment on a combined CV endpoint [8, 9] , although post hoc analyses suggest an advantage in some subgroups [16] . The recently published SHARP study, which included 9,720 patients with CKD (of whom 3,023 were on maintenance dialysis therapy), reported that allocation to simvastatin plus ezetimibe was associated with a 17% reduction in major atherosclerotic events [17] . However, the majority of patients in SHARP were not on dialysis and analysis of the subgroup of patients on HD did not show a benefit of lipid-lowering therapy. Therefore, in the face of a limited efficacy of preventative strategies that are proven and well established in other patient groups, there is a pressing need to identify risk factors (and potential therapeutic targets) for CV disease in patients with end-stage renal disease receiving HD.
In this post hoc analysis of the AURORA study, traditional CV risk factors such as smoking status, BMI, LDL-C or SBP were not associated with CV outcomes in HD patients, confirming previous reports [18, 19] . In contrast, the present study showed that non-traditional risk factors that are specific to end-stage renal disease play an important role for CV events in HD patients. In the multivariate analyses, older age, increased serum phosphate levels, lower serum albumin levels, preexisting CHD, years on HD, diabetes and increased CRP levels were independent risk factors for the primary endpoint MACE. Age was a risk factor for all pre-specified CV endpoints, including MACE, atherosclerotic cardiac events, and CV death. This confirms previous findings, such as those in an observational study of 34,741 dialysis patients by Roberts et al. [20] demonstrating that older age is a risk factor for CVD. Similarly, in a post hoc analysis from the randomized FOSIDIAL trial, the investigators also showed advanced age as a strong risk predictor for CV events in HD patients [21] . However, age is an unmodifiable risk factor, and the identification of potentially modifiable risk factors is of paramount importance. In the present study, we found that increased serum phosphate level was an independent risk factor for all endpoints. Various observational studies also suggest that serum phosphate level is a risk factor for CVD and mortality in HD patients [12, 13] . For example, in a cohort study in 9,076 HD patients, an elevated phosphate level was identified as a predictor of mortality, independent of parathyroid hormone [12] . In another study with 12,833 HD patients, higher phosphate levels were associated with increased CV mortality [13] . This is consistent with functional studies that have shown elevated phosphate to be associated with impaired endothelial function in vitro and in vivo [22] . Endothelial dysfunction, in turn, is closely correlated with arterial stiffness, which is a powerful determinant of CV events in HD patients [23] . Furthermore, as a structural mechanism, high phosphate levels may contribute to vascular calcification, which is closely related to arterial stiffness [24] . The results from our current analysis support the notion that maintaining serum phosphate in the normal range should be a major treatment goal to prevent CVD in HD patients. On the other hand, it is possible that high phosphorus reflects non-compliance with diet, missed, or shortened dialysis treatments all of which can affect mortality. Several clinical studies have demonstrated that elevated CRP levels and lower albumin levels are associated with increased CV mortality in HD patients [21, [25] [26] [27] [28] . In our current analysis, these parameters were also independent risk factors for all pre-specified CV endpoints. The common occurrence of inflammation, malnutrition and atherosclerosis in HD patients has led to the suggestion of pattern of disease termed malnutrition, inflammation, and atherosclerosis (MIA) syndrome [29] . This syndrome has been associated with mortality in dialysis patients [29, 30] . The FINE study, a prospective, randomised, controlled trial in 186 malnourished dialysis patients, demonstrated that improvement in the nutritional parameter pre-albumin, in response to nutritional supplements, was associated with a significant decrease in mortality [31] . Another randomised, controlled study from Recio-Mayoral et al. [32] in 76 CKD patients found that inflammation status correlates with endothelial dysfunction and the degree of atherosclerosis. Taken together with the findings of our large-scale study, these data suggest that interventions aimed at improving nutritional status and lowering the burden of inflammation, e.g. by using anti-cytokine therapy in HD patients [33] , may be an effective strategy to prevent CV events in these patients. However, caution is warranted. Despite large reductions in hsCRP of about 50% in the AURORA study, we found no reduction in CV outcomes. It is possible that the link between inflammation and mortality is not a causal one. Measurements of conventional risk factors such as blood pressure were not made using ambulatory blood pressure recordings, therefore we are unable to dismiss the effects of such recordings on hard outcomes.
In conclusion, although CV risk in patients receiving HD is increased 10-20 times to that of the general popu- 150 lation, the disease pattern, natural history and associated risk factors are very different. The AURORA trial demonstrated that rosuvastatin lowered LDL-C, but had no significant effects on CV events in nearly 3,000 HD patients followed for up to 4 years. We have used the AURORA trial database to explore risk factor relationships -for conventional and unconventional CV risk factors -for three independently validated CV endpoints. The results show that conventional risk factors, such as dyslipidaemia and smoking, have little impact on CV events, whereas elevated phosphate and evidence of inflammation are important potentially modifiable risk factors.
